Synthon completes acquisition of Nafar Laboratorios
Synthon announces its acquisition of Nafar Laboratorios - a developer, manufacturer and distributor of generic drugs to the Mexican market. Nafar has grown from a distributor of generic drugs broadly to an integrated company with its own research and development capabilities. They have successfully launched new products on a consistent basis, and have a proven track record of innovation - including the manufacturing and introduction of soft-gel formulations into the Mexican market.
Jacques Lemmens, founder of Synthon and head of Synthon's Supervisory Board comments: "Nafar is a great addition to our global expansion and joins other recent acquisitions in Chile and Argentina to create a growing presence in emerging markets. We are very excited about the potential of Nafar and the synergies available with our existing business".
Rudy Mareel, Synthon's CEO, highlights the strategic opportunity Nafar represents: "Synthon intends to focus strongly on emerging markets to expand. We are looking for organizations that have a strong reputation in their local markets and can integrate our future portfolio into their offerings, while at the same time delivering knowledge and expertise that will enable us to grow more rapidly. Nafar is a great fit to this strategy as we continue to explore additional opportunities in Latin America, Eastern Europe, and Asia Pacific."
About Synthon Synthon is an international pharmaceutical company which develops, manufactures and out-licenses specialty generics. Recently Synthon has started research and development in the biopharmaceutical area, which will result in a new generation of medicines. Employing more than 1250 staff worldwide, Synthon is headquartered in the Netherlands and has subsidiaries in eight other countries. Synthon offers a wide portfolio of generic products with many interesting early entry opportunities, which are made available worldwide through local marketing partners.